CAMBRIDGE

Cambridge University Press
978-1-107-69047-9 — Decision Making in Health and Medicine: Integrating Evidence and Values (2nd Edition) M. G. Myriam Hunink , Milton C. Weinstein , Eve Wittenberg , Michael F. Drummond , Joseph S. Pliskin , John B. Wong , Paul P. Glasziou
Index
More Information

Index

absorbing state models (Markov), 321
acceptability curve (CEA), 379–81, **380**
affect heuristic, 401–2, **402**
Airoldi, M., 264
Alf, E., 189
algorithms. *See also* derivation
  calibration, 347–9
  clinical, **21**, 21–2
Allais, M., 408
alternative weighing
  consequence modeling, 12–15, **13**, **14**
  decision tree, **9**, 9, **11**
  PROACTIVE, **25**
  trade-off estimation, 15–16
amortization (health-care costs), 252–4
analysis guidelines, 281–4
anchoring and adjusting heuristic, 142, 400
appraisal. *See* systematic review
articulation (individual), 97
assessing agreement (calibration), 345–7
attributes. *See* discrete choice experiments (DCE) (individual)
availability (probability)
  as subjective disease estimate, 141
  heuristic, 397–8
averaging out, 49–51, **50**, 62
aversion (risk), 104, 403–8
averted costs (CEA), 248–9

balance sheet, 13–15, **14**, 60–1, **61**, **148**
Barbieri, M., 284
Bayes' formula
  and data subjective probability, 234
  applying, 133
  derivation of, 132–3
  for multiple diseases, 205
  for multiple tests, 179
  for multivariable models, 183–6, **184**
  odds-likelihood-ratio form, 136–9, **137**
  to decision trees, 157
  with tree inversion, **134**, 134–5
bias
  data source, 220–1, **221**
  in heuristics, 397–402
  in summary estimates, 223–6
bootstrapping (dataset), 367
Boylston, Z., 53–6
Brazier, J., 263
Brown, M. L., 280

calibration. *See also* validity, estimation
  assessing agreement, 345–7
  definition, 344–5
  for multiple test validity, **190–2**
  parameter search strategies, 347–9
Cancer Intervention and Surveillance Modeling Network (CISNET), 351
categorical test results, 165, **180**
CEA. *See* cost-effectiveness analysis (CEA)
certainty
  effect, 409
  equivalent, 106

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-69047-9 — Decision Making in Health and Medicine: Integrating Evidence and Values (2nd Edition) M. G. Myriam Hunink , Milton C. Weinstein , Eve Wittenberg , Michael F. Drummond , Joseph S. Pliskin , John B. Wong , Paul P. Glasziou
Index
More Information

chained gamble, 93–4
chance tree, **12–13**, **134**, 134–5. *See also* survival curves
Claxton, K., 269
clinical algorithm, **21**, 21–2
clinical encounter (patient), 80–3, **84**
clinical studies (finding best), 211–16, **214**
Cochrane Library (database), 10–11, 216–17
cohort simulation (Markov evaluation tool)
  and heterogeneity, 362
  in recurring events, **307**, 307–15, **309**, **313**, **315**
combination
  of health measures, 259–64
  probability, **46**, **46**, 46–9, **49**
  test result, 179–86, **180**, **184**
communication (patient), 97
competing choice problem (CEA), 270, **273**, 273–4, 278–9, **279**
complexity
  of decision making, 1–3, 23
  of valuing outcomes, 99
components
  CEA, 244–5
  problem, 3
computer databases, 10–11, 213–17, **214**, 280
conditional independence (tests), 181–2
conditional probabilities, 47, 122–4
confidence interval, 47–8
confounder, 42
consequence modeling (PROACTIVE), 12–15, **13**
constrained resources
  and health outcomes, 264–9, **266**
  cost-effectiveness analysis, 269–80, **271**, **272**, **273**, **277**, **279**
  economic analysis, 245–58, 285–9
  effectiveness measures, 258–64
  efficient allocation of, 238–45, **240**
  guidelines, 281–3
  justice and equity in, 284–5
  transferring analysis data, 283–4
  uncertainty in, 280–1
construct validity (model), 349–50
Consumer Price Index (CPI), 254–5
continuous test results, 165, 171–7
control (of health-care costs), 239–41, **240**
controlled clinical trials
  for intervention benefits and risks, 10–11
cost–benefit analysis
  in monetary terms, 241
  valuing outcomes in, 257–8
cost-effectiveness analysis (CEA). *See also* net harm (treatment), net benefit (treatment)
  and societal decision making, 112–13
  cost components, 246–50
  effectiveness measures, 258–64
  mix of perspectives in, 240, 242–4
  model, 244–5
  uncertainty in, 375–81, **376**, **380**
  with constrained resources, 269–83, **271**, **272**, **273**, **277**, **279**
cost-effectiveness plane, **240**, 240
cost-minimization analysis, 240
costs. *See also* price
  and balance sheet, **14–15**
  and decision making, 96
  and risk, 104–5
  as economic resources, 238, 245–58
  joint distribution of, **377–81**
Cox proportional hazard model (survival), 337
CPI. *See* Consumer Price Index (CPI)
cross-validation (model), 351
curve
  acceptability, 379–81
  ROC, 172–6, 187–90, 205–6
  survival, 86–7, 302, 314–15, **335**, 335, **336**
cycle. *See also* time
  corrections in Markov models, 314–15, **315**
  in state-transition decision models, **304**, 304–5
  on cohort simulation, 305–6
cycle trees (Markov), 324–6, **325**, **326**

data
  ambiguity, 4
  availability and cycle length, 305
  clusters, 204

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-69047-9 — Decision Making in Health and Medicine: Integrating Evidence and Values (2nd Edition) M. G. Myriam Hunink , Milton C. Weinstein , Eve Wittenberg , Michael F. Drummond , Joseph S. Pliskin , John B. Wong , Paul P. Glasziou
Index
More Information

data sources
finding best, 209–11
meta-analysis for inconsistencies, **226**, 226, **230**
studies, 211–16, **214**
systematic reviews of, 216–26, **219**, **221**, **223**
decision analysis
and data sources, 209–11
and values, 80–5, **82**, **84**, 96–8
decision guides, 20–3
decision making. *See also* resource allocation
and truth, 231
and when to test, 145–6, **146**
best studies to use, **223**, 223–6
complexity of, 1–3, 23
paradigms, 109–13
psychological aspects of, 392–411
societal, 83–5
uncertainty in, 3–5
decision-making alternatives, 8–16, 18, 58–62
decision process models (Markov), 328–31
decision tree
alternatives, **11**
and diagnostic information, **59**, 59–60, **60**, 72–6, **73**, **75**
as combined chance tree, 17
becoming clinical algorithm, 21
compared to state-transition decision models, 300–2, **301**, **303**
definition, **9**
extensive form, 74
for positivity criterion, **194**
for threshold decisions, 157, 160
forms of, **73**, 73–4, **75**
sequencing decision nodes, **74–6**, **148**
strategic form, 74
with risky options, **55**
Declining Exponential Approximation of Life Expectancy (DEALE) estimation, 338–9
delta method (sensitivity analysis), 372–3, 387
derivation. *See also* algorithms
delta method (sensitivity analysis), 387
discounting costs, 264–7
value of information analysis, 387–8
diagnosis
versus prognosis, 178
Diagnostic Imaging for Coronary Artery Disease (DICAD) consortium, 167, **168**
diagnostic information
and Bayes' formula, 131–9, **134**, **137**
and disease probability estimates, 140–3
and probability, 118–31, **122**, **125**, **127**, **130**, **131**
expected value, 160–3, **161**
indices for dichotomous tests, 139–40
diagnostic tests. *See also* test results
in intervention selection, 11–12
diagnostic uncertainty, 34
disability-adjusted life years (DALYs), 98, 259–60, 262–4, 270–9, **271**, **272**, **273**, **276**, 284–5. *See also* quality of life
discount rate (economics), 269
discounting costs, 264–9, **265**
discrete choice experiments (DCE) (individual), 97–8
discrimination (in multiple-test validity), **187**, 187–90, **189**
disease
communicable, 242
multiple states of, 205
scales, 262
survival curves without, **310**
do-nothing alternative (decision making), **9**, 9–10, **11**
Dorfman, D. D., 189
dynamic transition models (Markov), 331–2

economic evaluation. *See* cost-effectiveness analysis (CEA)
effectiveness measures
CEA, 258–64
linear combinations of, 378–9
emergency conditions (treatment options in), 56–8
EQ-5D. *See* EuroQol health index (EQ-5D)

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-69047-9 — Decision Making in Health and Medicine: Integrating Evidence and Values (2nd Edition) M. G. Myriam Hunink , Milton C. Weinstein , Eve Wittenberg , Michael F. Drummond , Joseph S. Pliskin , John B. Wong , Paul P. Glasziou
Index
More Information

equivalence measures (outcomes metric), 96
estimation. *See also* validity. *See also* calibration
  parameter, **335**, 335, **336**, **342**
  trade-off, 15–16
ethics, 284–5. *See also* values
EuroQol health index (EQ-5D), 100–2, 112, 262–3
evidence
  hierarchy of, 209–10
expected net benefit of sampling (ENBS), 386
expected value. *See also* value of information analysis, uncertainty
  and balance sheet, 16–18, **17**
  definition, 16, 49–51, **50**
  of diagnostic information, **155**, 160–3, **161**
  optimization, 18–19, 62
expected value of clinical information (EVCI), 160–2. *See also* number-need-to-test
expected value of partial perfect information (EVPPI), 384–5
expected value of perfect information (EVPI), 160, **161**, 382–4
expected value of sample information (EVSI), 385
exploration (assumption), 19
extended dominance analysis (CEA), 274–8, **276**
extensive form (decision tree), **73**, 73–4, **75**
external validation (model), 351

face validity (model). *See* construct validity (model)
false-negative ratio (*FNR*), **122**, 123, **125**
false-positive ratio (*FPR*)
  and net proportional benefit, 201–3
  definition, **122**, 123, **125**
  multicategory test results, 171–7, **174**, **176**, **177**, **206**
Ferrer-I-Carbonell, A., 255
Fintor, L., 280
first-order uncertainty. *See* stochastic uncertainty
fitting. *See* calibration
folding back, 62
framing effects (Prospect theory), 403–5
Franklin, B., 53–4, 56
friction cost method (productivity), 256–7
Functional Capacity Index, 262
fundamental matrix solution (Markov evaluation tool), 307
fundamental objective, 8
future research
  multiple test results, 205–6
  needing to be justified through information analysis, 381–2
  population expected values, 383–6
  valuation methods, 107–9

gamblers. *See* seeking (risk)
genetic algorithms (calibration), 348–9
George, B., 286
goodness-of-fit. *See* assessing agreement (calibration)
Gravelle, H., 269
gray zone. *See* threshold
Grundy, 382

Hammond, J. S., 5
Hanson, K., 264
harms (potential)
  and balance sheet, **14–15**
health index
  cross-walking, 99
  utility assessment, **100**, 100–2
Health Utilities Index (HUI), 100–1, 262
health-care
  costs, 246, 249–55
  main focus, 7
health-care interventions (CEA cost), 246, 249–50
health-care resources (CEA cost), 251–5
health states
  worse than dead, 102
heterogeneity
  analyzing, 361–6, **362**
  and uncertainty types, **359**
  types of, 358

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-69047-9 — Decision Making in Health and Medicine: Integrating Evidence and Values (2nd Edition) M. G. Myriam Hunink , Milton C. Weinstein , Eve Wittenberg , Michael F. Drummond , Joseph S. Pliskin , John B. Wong , Paul P. Glasziou
Index
More Information

heuristics (in information processing), 397–402
hierarchy
  of evidence, 209–10
  simulations, 373–5, **374**
HUI. *See* Health Utilities Index (HUI)
human capital method (cost-benefit analysis), 257

incremental cost-effectiveness ratio (ICER), **376**, 376–9
independence (probabilistic), 47–8
index
  CPI, 254–5
  EQ-5D, 100–2, 112, 262–3
  HUI, 100–1, 262
  NRI, 199–200
  SF-6D, 100–1
  Youden's, 140
indices for dichotomous tests (diagnostic), 139–40
indices for multiple test results
  clinical utility, 197–203, **198**, **200**, **203**, **204**
  validity, 186–92, **187**, **189**, **191**
inflation, 254–5
information
  and anchoring heuristic, 400
  diagnostic, 72–6, **73**, **75**
  in intervention selection, 11–12
  partial perfect, 384–5
  perfect, 160, **161**, 382–4
  sample, 385
  value of analysis, 381–8
integrated discrimination improvement (*IDI*) index, 200–1
integration
  evidence, 16–18, **17**
  expected value optimization, 18–19
integration and exploration (PROACTIVE), **25**
internal validity (model), 350
International Society for Pharmacoeconomics and Outcomes Research, 283
intervention
  alternatives, 10–11, **11**
  and cost-effectiveness plane, **240**, 240
  effectiveness, 212
intuition (in decision making), 410–11

Jenner, E., 53
Johannesson, M., 250
joint probability, **48–9**

Kahneman, D., 393–4, 398–9, 403–9
Koopmanschap, M. A., 255–7

league tables (CEA), 280
life expectancy
  adding years to as analysis tool, 249–50
  and utility assessment, **105–6**
  calculating using cohort simulation, 308–10, **309**
  estimating variables in, 337–41
  in CEA, 264
  recurring events during. *See* Markov models
life table analysis, 335–6, **336**
likelihood ratio (*LR*)
  and calibration, 346
  definition, 138
  for dichotomous test, 138–40
  for multivariable models, 185–6
  in conditional independent tests, **180**, **180**, 182–3
  multicategory test results, **168**, **168**, 168
  result-specific, 175–6, **177**
  uninterpretable test results, 176–7, **177**
limited resources. *See* constrained resources
Loomes, G., 409
LR. *See* likelihood ratio (*LR*)

mapping rules (utility assessment), 101–2
Markov models
  cycle trees, 324–6
  decision process, 328–31
  dynamic transition, 331–2
  estimating probabilities in, 326–8
  evaluation tools for, 307–19

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-69047-9 — Decision Making in Health and Medicine: Integrating Evidence and Values (2nd Edition) M. G. Myriam Hunink , Milton C. Weinstein , Eve Wittenberg , Michael F. Drummond , Joseph S. Pliskin , John B. Wong , Paul P. Glasziou
Index
More Information

standard, 302–6
states, 319–24
MASS. *See* Multi-centre Aneurysm Screening Study (MASS)
Mather, C., 53–6
McNeil, B., 404
mean. *See* expected value
Medical Outcomes Study (SF-36), 88, 259–60, 263
MEDLINE (database), 214–15
Meltzer, D., 250
meta-analysis (data source), 225, 226, **230**
See also systematic review
microsimulation. *See also* Monte Carlo simulation (and state-transition models)
state-transition decision models, 362–5, **363**
using discrete stochastic event simulation, 365–6
modeling
consequence, 12–15, **13**, **14**, **25**
PROACTIVE, 20–3, **21**, 72–6
structure uncertainty, **359**, 373
validity in, 334, 349–52
money. *See* price, costs
monitoring (problem policy), 9–10
Monte Carlo simulation
See also microsimulation
for recurring events, 315–19, **316**, 328–30
of stochastic uncertainty, 366–7
sensitivity analysis, 368–72, **369**, **371**
more information alternative (decision making), **9**
Morton, A., 264
multicategory test results
post-test probability, 166–71, **168**, **168**, **170**
trade-offs, 171–7, **174**, **176**, **177**, **206**
Multi-centre Aneurysm Screening Study (MASS), 351–2
multiple test results
clustered data, 204
combining, 179–86, **180**, **184**
future research in, 205–6
indices of clinical utility, 197–203, **198**, **200**, **203**, **204**
indices of validity, 186–92, **187**, **189**, **191**
multiple disease states, 205
positivity criterion, 192–7, **194**, **197**
test threshold, 157
multivariable test models
Bayes' formula, 183–6
for multiple test validity, **197**
positivity criterion, 196–7, **197**

National Institute for Health and Clinical Excellence (UK), 112, 282, 286
National Institutes of Health (US), 282
natural history
and consequences, 12
potential dire consequences, 6
Nedler-Mead algorithm (calibration), 348
net benefit (treatment), *See also* cost-effectiveness analysis (CEA)
expected from sampling, 386
for multiple test validity, 201–3, **203**
foregone calculation, 381–2
linear combinations of, 378–9
positivity criterion, 195–6
treatment threshold, **64**, 67–8, **155**, 156
net harm (treatment), **64**, 68, 154–6, 195–6. *See also* cost-effectiveness analysis (CEA)
Net Reclassification Improvement (*NRI*) index, 199–200
neutral (risk), 104–5, **105**
no treat–test threshold, **146**, 147–54, 157
non-absorbing state models (Markov), **322**, 322, **324**
non-competing choice problem (CEA), 270–3, **271**, **272**, 278–9, **279**
NRI. *See* Net Reclassification Improvement (*NRI*) index
number-needed-to-test, 163. *See also* expected value of clinical information (EVCI)

objective (PROACTIVE), 7, **25**
odds. *See* probability

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-69047-9 — Decision Making in Health and Medicine: Integrating Evidence and Values (2nd Edition) M. G. Myriam Hunink , Milton C. Weinstein , Eve Wittenberg , Michael F. Drummond , Joseph S. Pliskin , John B. Wong , Paul P. Glasziou
Index
More Information

odds-likelihood-ratio form (Bayesian revision), 136–9, **136**, 166
opportunity cost, 238, 245–6, 251–5
ordinal test results, 165, 171–7
outcomes
  and balance sheet, 14
  and guideline creation, 20–1
  and values, 78–80, 85–6
  CEA measures of health, 258–64
  consequences, **13**, 13, **14**
  discounting costs, 264–9, **266**
  framing effects and, 403–5
  with constrained resources, 264–9, **266**

Panel on Cost-effectiveness in Health and Medicine (report), 289–95
parameter uncertainty, **368**, 368, **369**, **371**. *See also* probability
patients. *See also* society
  and values, 80–3, **84**, 109–11, 213, 260–1
  heterogeneity (Markov), 321
  heterogeneity across subgroups, 358, **359**
  screening (clinical), 80–3, **84**, 129–31, **130**, **131**
  wanting a shared decision with physician, 110
percentages. *See* probability
person trade-off. *See* equivalence measures (outcomes metric)
perspectives
  reframing from different, 7
  toward resource allocation, 242–4
physician
  and patient time constraints, 238–9
  individual clinical decision making, 109–11
point of indifference, **92**, 92, **95**
population. *See* society
positive predictive value, 125, 126
positivity criterion
  for multiple test results, 192–7, **194**, **197**
  multicategory test results, 171–7
posterior probability. *See* post-test probability
post-test probability
  definition, 120, 125
  for multiple tests, 179–86
  for positive and negative outcomes, 124–9, **125**, **127**
  multicategory test results, 166–71, **168**, **168**, **170**
  versus pre-test, **153**
practicality
  PROACTIVE, 23–4
  utility assessment, 103–4
predictive values, 125, 126
predictive validation (model), 351–2
preferences. *See* values
present value (discounting costs), 264–7
pre-test probability
  and prevalence, 120–4, **122**
  choices of reference for, 167
  definition, **120**, 125
  in screening, 129–31, **130**, **131**
  multicategory test results, 171
  prior probability. *See* pre-test probability
price. *See also* costs
  adjustments, 254–5
  in health-care arena, 251–2
PROACTIVE decision making approach
  analyzing alternative decisions, **9**, 9, **11**, **13**, **14**, 58–62, **59**, **61**
  definition, 5, **24–6**
  integration and exploration, 16–19, **17**, 62–72, **64**, **65**, **67**, **70**, **72**
  modeling, 20–3, **21**, 72–6
  problem, 5–8, **6**, 58
  reason for using, 23–4
probability. *See also* uncertainty
  and diagnostic information, 118–31, **122**, **125**, **127**, **130**, **131**
  chance tree, **12–13**
  combining, **46**, **46**, 46, **49**
  conditional, 47
  disease estimates, 140–3
  independence, 47–8
  joint, **48–9**
  Markov model, 326–8
  misperception of, 394

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-69047-9 — Decision Making in Health and Medicine: Integrating Evidence and Values (2nd Edition) M. G. Myriam Hunink , Milton C. Weinstein , Eve Wittenberg , Michael F. Drummond , Joseph S. Pliskin , John B. Wong , Paul P. Glasziou
Index
More Information

multiplication rules, **46**
notation, 131–2
revision, 120, 128, **130**
treatment threshold, 68
problem
competing choice, 270, **273**, 273–4, 278–9, **279**
defining, 23–4
PROACTIVE, 5–8, **6**, 58
shopping spree, 270–3, **271**
productivity (loss of), 247–8, 256–7
prognosis
versus diagnosis, 178
prognostic factors, 39
prognostic uncertainty, 36
proportions. *See* probability
Prospect theory, 403–9
psychology (in decision making), 392–411

QALYs. Quality-adjusted life years, 98, 113, 241, 244–5, 259–64, **271–9,** 293, **380**
quality of life. *See also* disability-adjusted life years (DALYs)
and expected utility, **311–12**
and utility assessment, 107–9
and values, **87–8**, 102

Raiffa, 382
ranking health states (valuation method), 97
rates (economic), 269, 326–8
rating scale. *See also* time trade-off, standard gamble
and utility values, 99
utility assessment, 89–91, **90**
rationality (in decisions)
alternatives to, 402–11
psychology of, 394
receiver operating characteristic (ROC) curve
and discrimination, **187**, 187–90, **188**
and *LR*, 175–6, **177**
challenge, 205–6
diagnostic tests, 172–5, **174**, **183**, **183**
reclassification (for multiple test validity), **198**, 198, **200**
reference case (CEA guidelines), 281–2
reference gamble. *See* standard gamble
reframing
PROACTIVE decision making approach, **25**
problems, 7
Regret theory, 409–10. *See also* Prospect theory
relative utility (for multiple test validity), 203, **204**
representativeness
as subjective disease estimate, 142
heuristic, 398–400
research (future)
multiple test results, 205–6
needing to be justified through information analysis, 381–2
population expected values, 383–6
valuation methods, 107–9
resource allocation. *See also* society, decision making
and economic analysis, 285–9
and health outcomes, 264–9, **266**
and societal decision making, 111–13
constrained, 238–45, **240**
cost-effectiveness analysis, 269–80, **271**, **272**, **273**, **276**, **279**
economic costs, 245–58
effectiveness measures, 258–64
guidelines, 281–3
justice and equity in, 284–5
societal priorities, 237–8
transferring analysis data, 283–4
uncertainty in, 280–1
results
ability to change treatment choice, 152
algorithms in, **21**, 21–2
balance sheet in, 22
decision guide, 20–1
diagnostic test, **119**
variation in study, **226**
revealed preference method (outcome metric), 97
risk. *See also* toll (testing), Prospect theory
action threshold, 53–4

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-69047-9 — Decision Making in Health and Medicine: Integrating Evidence and Values (2nd Edition) M. G. Myriam Hunink , Milton C. Weinstein , Eve Wittenberg , Michael F. Drummond , Joseph S. Pliskin , John B. Wong , Paul P. Glasziou
Index
More Information

risk. (cont.)
and heuristics, 397–402
and uncertainty in modeling, 361
and utility assessment, 104–5, **105**
aversion, 104, 403–8
psychology of, 395–6
seeking, 407
risk factors. *See* prognostic factors
Robberstad, B., 264
ROC. *See* receiver operating characteristic (ROC) curve
rolling back, 62
Rushby, J. F., 264

safety netting. *See* monitoring (problem policy)
Schlaifer, 382
Schulz, K. F., 221
screening (clinical)
and pre-test probability, 129–31, **130**, **131**
patient encounter, 80–3, **84**
searching strategy (electronic), 213–16, **214**
seeking (risk), 104
sensitive test, 122–4, 139–40
sensitivity, 122, 125
sensitivity analysis
and data sources, 234–5
CEA, 280–1
definition, 63
for parameter uncertainty, **368**, 368, **369**, **371**
in dichotomous test, 19, 63, 65–6, **67**, 71–2, **72**
to analyze heterogeneity, 361
toll threshold, **159**
sequencing
CEA costs, 248–9
in Monte Carlo simulations, **316–18**
sequencing decision nodes
breaking problems down into, **301**
importance of, 135
SF-36. *See* Medical Outcomes Study (SF-36)
SF-6D. *See* Short-Form 6 dimensions health index (SF-6D)
shopping spree problem, 270–3, **271**
Short-Form 6 dimensions health index (SF-6D), 100–1
single measures of health (CEA), 258–9
Smith, D., 269
snowballing, 219
society. *See also* resource allocation, patients
and decision making, 83–5
and emotional policy making, 394–5
DALYs, 98
diagnostic testing for, 118
heterogeneity in, 358, **359**
heuristics in, 398, 401–2
outcomes metric, 96
perspectives in, 243
population EVPI, 383–4
specific test, 122–4, 139–40
specificity, 123, 125
standard gamble. *See also* uncertainty, time trade-off, rating scale
and risk preference, 105
utility assessment, 91–4, **92**
Stason, W. B., 268
stated preference method (outcome metric), 97
states
disease, 205
Markov model, 319–24
state-transition models
cohort simulation, **307**, 307–15, **309**, **313**, **315**
compared to decision trees, 300–2, **301**
decision process models, 328–31
dynamic transition models, 331–2
estimating life expectancy, 340–1
estimating probabilities, 326–8
fundamental matrix solution, 307
Markov cycle trees, 324–6, **325**, **326**
Markov models, 302–6, **304**
Markov states, **319**, **320**, **322**, **324**
microsimulation, 362–5
Monte Carlo simulation, 315–19, **316**, 328–30
stereotypes. *See* representativeness
stochastic process, 306, 365–6
stochastic uncertainty, 366–7

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-69047-9 — Decision Making in Health and Medicine: Integrating Evidence and Values (2nd Edition) M. G. Myriam Hunink , Milton C. Weinstein , Eve Wittenberg , Michael F. Drummond , Joseph S. Pliskin , John B. Wong , Paul P. Glasziou
Index
More Information

strategic form (decision tree), **73**, 73–4, **75**
strategy
  definition, 10
  electronic search, 213–16, **214**
studies
  bias in, 220–1, **221**
  finding best, 211–16, **214**
  original, 218–19, **219**
  primary, 217
study
  and results variation, **226**
  MASS, 351–2
  SF-36, 88, 259–60, 263
subjective probability, 227–34, **230**
Sugden, R., 409
summary estimates (data source), **223–6**
survival curves. *See also* chance tree
  and half-cycle correction, 314–15, **315**
  and values, 86–7
  estimating variables in, **335**, 335, **336**
  estimation, **334–7**
  in recurring models, 302
systemic review, 216–26, **219**, **221**, **223**

temporary states (Markov), **319**, 319–20
test and treat alternative, **146**
test results. *See also* diagnostic tests
  dichotomous, 166
  multicategory, 165–71
  multiple, 186–97, 205
  test variable in, 171–7
testing (dichotomous)
  and disease modeling, **74–6**
  and probability, **119**, 119, **122**, **125**, **127**, **130**, **131**
  deciding when to, 145–6, **146**
  number-need-to-test, 163
  test thresholds, **151**, 152, **153**, **155**
  with a toll, 158–60
testing (multicategory), 165–71
test–treat threshold, **146**, **147–51**, 152–4, **153**, 157
threshold
  test, **151**, 152, **153**, **155**
  treatment, 53–4, **64**, 64, **65**, **70**
Tilling, C., 248
time. *See also* cycle
  as a constrained resource, 238–9
  as CEA cost, 247, 255–6
  discounting, 312
  dynamic variable events, 331–2
  heuristics used as short-cut, 397
  life table analysis, 335–6, **336**
  preferences, **105–6**
  PROACTIVE, 23–4, 26
  prognosis expressed using, 178
  stochastic uncertainty over, **359**, 360
  trade-offs, 94–6, **95**, **95**
time trade-off, 94–6, **95**, **95**. *See also* standard gamble, rating scale
toll (testing), 158–60, **159**, 162–3, 326. *See also* risk
tools (Markov evaluation), 307–19
Torrance, G. W., 99
tracker variables (Monte Carlo simulation), 329, 341–2, 362–5, **363**
trade-offs
  identification of, 15–16, 56
  multicategory test results, 171–7, **174**, **176**, **177**, **206**
  PROACTIVE, **25**, 62
  time, 94–6, **95**, **95**
treatment
  best option under diagnostic uncertainty, 56–72, **59**, **61**, **64**, **65**, **67**, **70**, **72**
  best risky, **54–6**
  efficacy, 341
  threshold, 53–4, **63**, 64, **65**, **70**
  uncertainty in, 4, 41
treatment now alternative (decision making), **9**
treatment threshold, **63**–71, 146–51, **148**, **150**
tree
  chance, **12–13**, **134**, 134–5
  cycle, 324–6, **325**, **326**
  decision, 9, **11**, 17, 21, **55**, 59–60, 72–6, 157, 160, 300–2
triggering (problem policy), 10

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-69047-9 — Decision Making in Health and Medicine: Integrating Evidence and Values (2nd Edition) M. G. Myriam Hunink , Milton C. Weinstein , Eve Wittenberg , Michael F. Drummond , Joseph S. Pliskin , John B. Wong , Paul P. Glasziou
Index
More Information

true-negative ratio (*TNR*), **122**, 123–4, **125**, **127**
true-positive ratio (*TPR*)
  and net proportional benefit, 201–3, **203**
  as conditional probability, **122–4**, **125**, **127**
  multicategory test results, 171–7, **174**, **176**, **177**, **206**
tunnel states (Markov), **320**, 320
Tversky, A., 393–4, 398–9, 403–9

uncertainty
  and calibration, 344–5
  and heterogeneity, 356–8, 373–5, **374**
  diagnostic, 56–72, **59**, **61**, **64**, **65**, **70**, **72**, 146
  in CEA, 375–81, **376**, **380**, **380**
  in decision making, 3–5
  model structure, **359**, 361, 373
  parameter, 360, **368**, 368, **369**, **371**
  residual, 56–8
  stochastic, 360, 366–7
  types of, **359**, 360–1
US Public Health Service (USPHS) CEA guidelines, 281–2
utility
  definition, 90
  function, 90
utility assessment. *See also* values
  and CEA, 112, 260
  and life expectancy, **105–6**
  and quality of life, 107–9
  health index, **100**, 100–2
  off-the-shelf, 102
  patient risk, 104–5, **105**
  practicality, 103–4
  preference-based measures, 88–99, 259
  rating scale, 89–91, **91**, 99
  relationship between types of, 98–100
  standard gamble, 91–4, **92**
  time trade-off, 94–6, **95**, **95**

validity. *See also* estimation, calibration
  decision model, 334, 349–52
  test result, 186–203
value of information analysis, 381–8
value optimization
  and trade-offs, 15
  improved quality of life, 8
  PROACTIVE decision-making approach, **25**
  pulmonary embolism (PE), 87–8
values. *See also* utility assessment, ethics
  and clinical algorithm, 22
  and outcomes, 78–80, 85–6, 98
  and quality of life, **87–8**, 102, 259–63
  as patient bias, 142–3
  decision aids for, 22, 80–5, **82**, **84**, 96–8
  time as, **95**
Van den Berg, B., 255
verification (model), 350
visual aids (utilities assessment), **95**, 103–4

wait-and-see alternative (decision making), **6**, **9**, 9–10, 13–14, **14**
watchful waiting alternative (decision making), **9**, 9–10, 56
Weinstein, M. C., 268
what-if analysis. *See* sensitivity analysis
willingness-to-pay method (cost–benefit analysis), 257–8
  for valuing outcomes, 96
World Bank, 98, 263
World Health Organization (WHO), 98, 264

Youden's index, 140

© in this web service Cambridge University Press www.cambridge.org